ZEUCF yields 52631.58% · PFE yields 6.13%● Live data
📍 ZEUCF pulled ahead of the other in Year 1
Combined, ZEUCF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ZEUCF + PFE for your $10,000?
ZeU Technologies Inc. engages in the block-chain technology development business. The company offers distributed ledger technology (DLT)-based secure email system, which authenticates the sender and the recipient, encrypts the data, and stores it on the distributed storage service; random numbers generation technology to create actual random numbers; cross-chain transactions technology; transactional decentralized communication protocol infrastructure, a system that removes the smart contract layer; distributed data real-time backup and recovery, a system for realizing real-time data backup and recovery based on DLT; converting database applications into DLT applications; biocrypt digital wallet technology, a biometric digital wallet for the cold storage of cryptocurrencies; augmenting database applications technology with DLT; and symmetric asynchronous generative encryption technology for security of data. It also provides Mula platform, a modular platform that anonymizes and protects a user's online information; MulaMail, an enterprise solution; safe custody of private data using blockchain technology; and permission-based multi-level encryption scheme document for decentralized storage. In addition, the company offers virtual identity and user management infrastructure; ZeU Gaming platform; and ZeUPay for custodial and legacy banking support for the Mula platform, as well as operates mula.education, which allows users to practice the encryption methods used in the Mula platform. The company was formerly known as ZeU Crypto Networks Inc. and changed its name to ZeU Technologies Inc. in October 15, 2020. ZeU Technologies Inc. was incorporated in 2018 and is headquartered in Montreal, Canada.
Full ZEUCF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.